The Effect of De-Prescribing Antipsychotics on Health and Quality of Life for People With Dementia

Completed · Has a placebo group

Conditions studied: Alzheimer Disease, Dementia, Prescribing, Off-Label

In brief

This study aims to analyze how warning letters sent to physicians prescribing high levels of the antipsychotic quetiapine affected the health and quality of life of their patients with dementia. Using a randomized controlled trial conducted by the Centers for Medicare and Medicaid Services (CMS) in 2015, this secondary study looks at the effects of potential de-prescribing of antipsychotics by study physicians induced by the letters. The central question is whether the intervention led to better health and quality of life outcomes by encouraging more guideline-concordant care and whether changes in physicians' prescription behavior caused unintended harms.

Key facts

Study ID
NCT05172687
Run by
Columbia University
People needed
336460
Starts
2015-04-01
Expected to finish
2018-12-31
Last updated by the study team
2024-02-13

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.